ETF Holdings Breakdown of APLS

News associated with APLS

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Acquired by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lifted its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 147.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 74,325 shares of the company’s stock after buying an additional 44,332 shares during the quarter. Assenagon Asset Management S.A.’s […] - 2025-06-18 07:42:57

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stake Lifted by Merit Financial Group LLC

Merit Financial Group LLC increased its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 324.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,762 shares of the company’s stock after buying an additional 25,806 shares during the quarter. Merit […] - 2025-06-09 08:46:43

Wealth Enhancement Advisory Services LLC Purchases 19,641 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Wealth Enhancement Advisory Services LLC increased its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 140.8% during the 4th quarter, Holdings Channel reports. The firm owned 33,594 shares of the company’s stock after purchasing an additional 19,641 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Apellis Pharmaceuticals were […] - 2025-06-09 07:48:45

Apellis Pharmaceuticals (NASDAQ:APLS) Trading Up 7.7% on Analyst Upgrade

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) shot up 7.7% during mid-day trading on Monday after Wells Fargo & Company raised their price target on the stock from $26.00 to $29.00. Wells Fargo & Company currently has an equal weight rating on the stock. Apellis Pharmaceuticals traded as high as $18.50 and […] - 2025-06-04 05:01:06

Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $29.00

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target increased by Wells Fargo & Company from $26.00 to $29.00 in a research report released on Monday,Benzinga reports. They currently have an equal weight rating on the stock. APLS has been the subject of a number of other reports. Wedbush cut their price objective on […] - 2025-06-03 05:52:45

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Position Raised by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 11.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 212,887 shares of the company’s stock after buying an additional 21,822 shares during the quarter. UBS AM a […] - 2025-06-02 08:32:58

14,564 Shares in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Purchased by Vident Advisory LLC

Vident Advisory LLC purchased a new stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 14,564 shares of the company’s stock, valued at approximately $465,000. Several other institutional investors and hedge funds have also recently […] - 2025-05-28 08:31:01

Captrust Financial Advisors Buys Shares of 12,629 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Captrust Financial Advisors purchased a new position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) during the fourth quarter, Holdings Channel.com reports. The fund purchased 12,629 shares of the company’s stock, valued at approximately $403,000. Several other hedge funds have also made changes to their positions in APLS. Teacher Retirement System of Texas […] - 2025-05-20 07:47:07

Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 52-Week Low on Analyst Downgrade

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) reached a new 52-week low on Wednesday after Mizuho lowered their price target on the stock from $30.00 to $20.00. Mizuho currently has a neutral rating on the stock. Apellis Pharmaceuticals traded as low as $16.61 and last traded at $16.69, with a volume of […] - 2025-05-16 06:00:51

Ameriprise Financial Inc. Boosts Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Ameriprise Financial Inc. boosted its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 2.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 882,801 shares of the company’s stock after purchasing an additional 22,507 shares during the period. […] - 2025-05-14 10:10:45

Bank of America Corp DE Has $53.62 Million Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Bank of America Corp DE increased its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 72.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,680,213 shares of the company’s stock after purchasing an additional 705,209 shares during the period. Bank of […] - 2025-05-14 09:12:50

The Manufacturers Life Insurance Company Decreases Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

The Manufacturers Life Insurance Company cut its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 13.6% in the fourth quarter, Holdings Channel.com reports. The fund owned 52,897 shares of the company’s stock after selling 8,324 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Apellis Pharmaceuticals were worth $1,688,000 as of […] - 2025-05-12 09:10:47

Apellis Pharmaceuticals (NASDAQ:APLS) Cut to Outperform at Raymond James

Raymond James cut shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) from a strong-buy rating to an outperform rating in a research note released on Friday, MarketBeat reports. They currently have $52.00 price target on the stock, down from their previous price target of $75.00. Other equities research analysts have also issued reports about the […] - 2025-05-12 08:12:48

Apellis Pharmaceuticals (NASDAQ:APLS) Lowered to Neutral Rating by Bank of America

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) was downgraded by investment analysts at Bank of America from a “buy” rating to a “neutral” rating in a research note issued to investors on Friday, Marketbeat Ratings reports. They currently have a $23.00 target price on the stock, down from their previous target price of $41.00. Bank […] - 2025-05-11 08:40:50

Robert W. Baird Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $47.00

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price objective trimmed by Robert W. Baird from $55.00 to $47.00 in a report released on Thursday,Benzinga reports. The firm currently has an outperform rating on the stock. A number of other research analysts have also weighed in on APLS. HC Wainwright reiterated a “buy” rating and […] - 2025-05-11 08:40:50

Apellis Pharmaceuticals (NASDAQ:APLS) Hits New 52-Week Low Following Weak Earnings

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) hit a new 52-week low during trading on Wednesday following a weaker than expected earnings announcement. The stock traded as low as $16.65 and last traded at $18.78, with a volume of 490307 shares. The stock had previously closed at $19.12. The company reported ($0.74) […] - 2025-05-08 06:08:52

Legal & General Group Plc Sells 10,879 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Legal & General Group Plc decreased its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 11.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 86,771 shares of the company’s stock after selling 10,879 shares during the quarter. Legal & General Group Plc […] - 2025-04-24 08:18:56

Apellis Pharmaceuticals (NASDAQ:APLS) Shares Down 4.9% After Analyst Downgrade

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) shares fell 4.9% during mid-day trading on Tuesday after Royal Bank of Canada lowered their price target on the stock from $24.00 to $21.00. Royal Bank of Canada currently has a sector perform rating on the stock. Apellis Pharmaceuticals traded as low as $17.52 and last traded […] - 2025-04-24 05:15:10

Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $21.00 at Royal Bank of Canada

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its target price trimmed by Royal Bank of Canada from $24.00 to $21.00 in a report issued on Monday morning,Benzinga reports. The brokerage currently has a sector perform rating on the stock. Several other analysts have also commented on APLS. JPMorgan Chase & Co. lifted their price objective […] - 2025-04-22 05:54:45

Cerity Partners LLC Boosts Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Cerity Partners LLC lifted its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 48.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 46,667 shares of the company’s stock after acquiring an additional 15,286 shares during […] - 2025-04-18 09:24:57

Bank of Montreal Can Raises Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Bank of Montreal Can lifted its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 105.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 80,991 shares of the company’s stock after buying an additional 41,635 shares during the […] - 2025-04-17 08:42:51

KLP Kapitalforvaltning AS Takes $504,000 Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

KLP Kapitalforvaltning AS bought a new stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 15,800 shares of the company’s stock, valued at approximately $504,000. Several other hedge funds also […] - 2025-04-04 07:51:09

Prudential Financial Inc. Sells 89,700 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Prudential Financial Inc. trimmed its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 31.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 198,060 shares of the company’s stock after selling 89,700 shares during the period. Prudential Financial Inc. owned approximately 0.16% of Apellis […] - 2025-03-31 08:22:45

Signaturefd LLC Purchases 918 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Signaturefd LLC increased its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 357.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,175 shares of the company’s stock after acquiring an additional 918 shares during the quarter. Signaturefd LLC’s holdings in Apellis […] - 2025-03-26 07:48:50

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) have been assigned an average rating of “Moderate Buy” from the nineteen research firms that are presently covering the firm, MarketBeat.com reports. Eight analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and one has given a strong buy […] - 2025-03-06 08:26:27

JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Apellis Pharmaceuticals (NASDAQ:APLS) Stock

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) had its price target lifted by research analysts at JPMorgan Chase & Co. from $50.00 to $54.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would suggest a […] - 2025-03-06 08:26:26

Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $29.00 at Wedbush

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) had its price objective reduced by equities research analysts at Wedbush from $30.00 to $29.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has a “neutral” rating on the stock. Wedbush’s price objective would indicate a potential upside of 15.77% from the stock’s […] - 2025-03-05 06:44:52

Apellis Pharmaceuticals (NASDAQ:APLS) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) in a research note published on Monday,Benzinga reports. HC Wainwright currently has a $57.00 price objective on the stock. A number of other brokerages have also commented on APLS. Citigroup dropped their price objective on shares of Apellis Pharmaceuticals from […] - 2025-03-04 06:50:55

Analyzing Apellis Pharmaceuticals (NASDAQ:APLS) & Aprea Therapeutics (NASDAQ:APRE)

Aprea Therapeutics (NASDAQ:APRE – Get Free Report) and Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation. Profitability This table compares Aprea Therapeutics and Apellis […] - 2025-02-26 06:23:06

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Short Interest Update

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) was the target of a large decline in short interest in January. As of January 31st, there was short interest totalling 17,060,000 shares, a decline of 5.4% from the January 15th total of 18,040,000 shares. Based on an average daily trading volume, of 2,640,000 shares, the short-interest […] - 2025-02-19 08:46:10

APLS institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-06-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	50,889	USD 936,358
2025-06-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	8,789	USD 161,718
2025-06-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	62,720	USD 1,154,048
2025-06-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	62,720	USD 1,154,048
2025-06-26	IE000NITTFF2 (iShares Russell 1000 Growth UCITS ETF)	1,131	USD 20,810
2025-06-26	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	413	USD 7,599
Total =		186,662	USD 3,434,581

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer